Fri, Aug 1, 2014, 9:32 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Pharmacyclics Inc. Message Board

  • popeyethesailor61 popeyethesailor61 Oct 10, 2013 11:43 PM Flag

    Two targets for the price of one - (google it)

    Although ibrutinib has been found to be a potent inhibitor of BTK and downstream signaling of the BCR pathway, data have also been generated that suggest that ibrutinib can inhibit other important pathways. Studies have shown that ibrutinib is able to inhibit activation and function of human basophils. BTK is also able to inhibit the secretion of tumor necrosis factor-α, IL-1β, and IL-6 from primary monocytes, particularly those present in autoimmune arthritis.6 Furthermore, BTK inhibition inhibits the release of histamine, tumor necrosis factor-α, IL-8, and monocyte chemoattractant protein-1 from activated human mast cells. In B-cell malignancies such as multiple myeloma, BTK inhibition also inhibits multiple cytokines and chemokines secreted by autoclasts and bone marrow stromal cells. Furthermore, BTK inhibition with ibrutinib also decreased stromal cell-derived factor-1–induced migration of multiple myeloma cells and down-regulated macrophage-inflammatory protein-1α in multiple myeloma cells.7

 
PCYC
116.91-3.53(-2.93%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.